Emerging drugs for the treatment of primary biliary cholangitis
| Autor: | Naw April Phaw, Jessica K Dyson, David Jones |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Senescence
medicine.medical_specialty Cholagogues and Choleretics Chenodeoxycholic Acid 030226 pharmacology & pharmacy Gastroenterology 03 medical and health sciences 0302 clinical medicine Drug Development Fibrosis Internal medicine medicine Animals Humans Pharmacology (medical) Pharmacology Primary (chemistry) business.industry Liver Cirrhosis Biliary Ursodeoxycholic Acid End stage liver disease medicine.disease digestive system diseases 030220 oncology & carcinogenesis Disease Progression Quality of Life Cholestatic liver disease business |
| Zdroj: | Expert opinion on emerging drugs. 25(2) |
| ISSN: | 1744-7623 |
| Popis: | Primary biliary cholangitis (PBC) is a progressive inflammatory autoimmune cholestatic liver disease. Without treatment, it may result in fibrosis and eventually end stage liver disease. In addition to the disease burden, the symptom impact on the quality of life for PBC patients is significant. Ursodeoxycholic acid, and the second-line therapy, Obeticholic acid, are the only available licensed treatments. Although there has been rapid development of novel therapies in recent years for the treatment of PBC, there are very few symptoms directed therapies.This literature review aims to review the current treatment landscape in PBC and to explore how the next few years may unfold in the field. The current guidelines and emerging therapies in phase 2, 3 and 4 clinical trials have been included.The currently available therapies are effective, but their use has limitations and challenges and there is still significant unmet need. Although there have been promising therapeutic interventions in recent years, further research into personalizing therapeutic strategies with available treatments and new agents is needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|